Around two-thirds of patients treated for breast cancer will have had hormone-sensitive tumors and, after their initial treatment, will be advised to undergo hormone therapy for five to 10 years to prevent recurrence. But around half of these patients will for various reasons decide to discontinue these drugs early and face increased risk of recurrence.